ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2026
Biocontrol of Staphylococcus aureus in dairy products using lytic bacteriophage UHP46: efficacy in milk, cheese, and yogurt.
Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Staphylococcus aureus is a major public health concern in the dairy industry. It is a well-recognized pathogen responsible for bovine mastitis and raw milk contamination; certain strains produce heat-stable enterotoxin capable of causing staphylococcal food poisoning in humans. The emergence of multiple drug-resistant strains of S. aureus has rendered ineffective the use of antibiotics for control purposes. This study determined the antibacterial activity of lytic bacteriophage UHP46 against a single, previously characterized multidrug-resistant mastitis isolate, S. aureus S46, in three dairy matrices - milk, cheese and yogurt - under storage conditions representing refrigerated storage (4 °C), ambient conditions (25 °C) and a 37 °C mechanistic reference condition. UHP46 significantly reduced S. aureus S46 counts in milk, achieving reductions of 3.2 and 3.7 log₁₀ CFU/mL after 4 and 24 h at 4 °C, 2.1 and 3.1 log₁₀ CFU/mL after 4 and 24 h at 25 °C, and 1.8 log₁₀ CFU/mL after 3 h at 37 °C. The reduction at 37 °C was accompanied by an increase in phage titer from 7.2 to 8.8 log₁₀ PFU/mL. Application of UHP46 to cheese resulted in an immediate reduction of 0.6 log₁₀ CFU/g after 5 min of treatment at room temperature. The maximum reduction observed was 2.0 log₁₀ CFU/g at 24 h, with a sustained reduction of 1.9 log₁₀ CFU/g maintained through 96 h of refrigerated storage at 4 °C. In yogurt, net reductions on day 6 were 2.8, 2.7, and 1.6 log₁₀ CFU/g at 37 °C, 25 °C, and 4 °C, respectively. The findings indicate that UHP46 exhibits significant antibacterial activity against S. aureus S46 within the tested dairy matrices and under the evaluated storage conditions. However, as all challenge experiments utilized a single host strain, its efficacy against a broader panel of S. aureus, including methicillin-resistant S. aureus (MRSA), remains to be determined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.